Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells

Oncogene

Volumn 27, Issue 26, 2008, Pages 3746-3753

  Hsieh, S H ^a   Ying, N W ^a   Wu, M H ^a   Chiang, W F ^b   Hsu, C L ^c   Wong, T Y ^a   Jin, Y T ^a   Hong, T M ^d   Chen, Y L ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Endothelial cells; Galectin 1; Neuropilin 1; Oral cancer

Indexed keywords

GALECTIN 1; NEUROPILIN 1; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1; VASCULOTROPIN 165; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SQUAMOUS CELL CARCINOMA; VASCULAR ENDOTHELIUM; CELL MOTION; DRUG ANTAGONISM; ENDOTHELIUM CELL; METABOLISM; MOUTH TUMOR; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL MOVEMENT; ENDOTHELIAL CELLS; GALECTIN 1; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MOUTH NEOPLASMS; NEUROPILIN-1; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 45949085841     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1211029     Document Type: Article

References (30)

1. Camby I, Le Mercier M, Lefranc F, Kiss R. (2006). Galectin-1: a small protein with major functions. Glycobiology 16: 137R-157R.
2. Castro-Rivera E, Ran S, Thorpe P, Minna JD. (2004). Semaphorin 3B (SEMA3B)induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci USA 101: 11432-11437.
3. Chiang WF, Liu SY, Fang LY, Lin CN, Wu MH, Chen YC et al. (2007). Overexpression of galectin-1 at the tumor invasion front is associated with poor prognosis in early-stage oral squamous cell carcinoma. Oral Oncol (in press).
4. Clausse N, van den Brule F, Waltregny D, Garnier F, Castronovo V. (1999). Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis 3: 317-325.
5. Elola MT, Chiesa ME, Alberti AF, Mordoh J, Fink NE. (2005). Galectin-1 receptors in different cell types. J Biomed Sci 12: 13-29.
6. Ferrara N, Gerber HP, LeCouter J. (2003). The biology of VEGF and its receptors. Nat Med 9: 669-676.
7. Fischer C, Sanchez-Ruderisch H, Welzel M, Wiedenmann B, Sakai T, André S et al. (2005). Galectin-1 interacts with the \{alpha\. J Biol Chem 280: 37266-37277.
8. Fons P, Herault JP, Delesque N, Tuyaret J, Bono F, Herbert JM. (2004). VEGF-R2 and neuropilin-1 are involved in VEGF-A-induced differentiation of human bone marrow progenitor cells. J Cell Physiol 200: 351-359.
9. Gaudet AD, Steeves JD, Tetzlaff W, Ramer MS. (2005). Expression and functions of galectin-1 in sensory and motoneurons. Curr Drug Targets 6: 419-425.
10. Glinsky VV, Huflejt ME, Glinsky GV, Deutscher SL, Quinn TP. (2000). Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on beta- galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells. Cancer Res 60: 2584-2588.
11. Gu M, Wang W, Song WK, Cooper DN, Kaufman SJ. (1994). Selective modulation of the interaction of alpha 7 beta 1 integrin with fibronectin and laminin by L-14 lectin during skeletal muscle differentiation. J Cell Sci 107: 175-181.
12. He J, Baum LG. (2006). Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration. Lab Invest 86: 578-590.
13. Hong TM, Chen YL, Wu YY, Yuan A, Chao YC, Chung YC et al. (2007). Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer Res 13: 4759-4768.
14. Hu B, Guo P, Bar-Joseph I, Imanishi Y, Jarzynka MJ, Bogler O et al. (2007). Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene 26: 5577-5586.
15. Jung EJ, Moon HG, Cho BI, Jeong CY, Joo YT, Lee YJ et al. (2007). Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 120: 2331-2338.
16. Kadri T, Lataillade JJ, Doucet C, Marie A, Ernou I, Bourin P et al. (2005). Proteomic study of Galectin-1 expression in human mesenchymal stem cells. Stem Cells Dev 14: 204-212.
17. Konigsberg W, Kirchhofer D, Riederer MA, Nemerson Y. (2001). The TF:VIIa complex: clinical significance, structure-function relationships and its role in signaling and metastasis. Thromb Haemost 86: 757-771.
18. Murga M, Fernandez-Capetillo O, Tosato G. (2005). Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood 105: 1992-1999.
19. Neufeld G, Cohen T, Shraga N, Lange T, Kessler O, Herzog Y. (2002). The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc Med 12: 13-19.
20. Ozeki Y, Matsui T, Yamamoto Y, Funahashi M, Hamako J, Titani K. (1995). Tissue fibronectin is an endogenous ligand for galectin-1. Glycobiology 5: 255-261.
21. Parsons-Wingerter P, Kasman IM, Norberg S, Magnussen A, Zanivan S, Rissone A et al. (2005). Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors. Am J Pathol 167: 193-211.
22. Rabinovich GA. (2005). Galectin-1 as a potential cancer target. Br J Cancer 92: 1188-1192.
23. Rorive S, Belot N, Decaestecker C, Lefranc F, Gordower L, Micik S et al. (2001). Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 33: 241-255.
24. Shintani Y, Takashima S, Asano Y, Kato H, Liao Y, Yamazaki S et al. (2006). Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling. EMBO J 25: 3045-3055.
25. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S. (2006). Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 103: 15975-15980.
26. Toscano MA, Bianco GA, Ilarregui JM, Croci DO, Correale J, Hernandez JD et al. (2007). Differential glycosylation of T(H)1, T(H)2 and T(H)-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 8: 825-834.
27. Vaisman N, Gospodarowicz D, Neufeld G. (1990). Characterization of the receptors for vascular endothelial growth factor. J Biol Chem 265: 19461-19466.
28. Valenzuela HF, Pace KE, Cabrera PV, White R, Porvari K, Kaija H et al. (2007). O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1. Cancer Res 67: 6155-6162.
29. van den Brule FA, Waltregny D, Castronovo V. (2001). Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J Pathol 193: 80-87.
30. Zhou Q, Cummings RD. (1993). L-14 lectin recognition of laminin and its promotion of in vitro cell adhesion. Arch Biochem Biophys 300: 6-17.